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Interleukin-6iscurrentlyattractingsigniﬁcantinterestasapotentialtherapeutictargetinsystemicsclerosis(SSc).Inthispaper,the
biology of interleukin-6 is reviewed, and the evidence for interleukin-6 dysregulation in SSc is explored. The role of inteleukin-6
classical and trans signalling pathways in SSc relevant phenomena such as chronic inﬂammation, autoimmunity, endothelial cell
dysfunction, and ﬁbrogenesis is discussed. The existing evidence that interventions designed to block interleukin-6 signalling are
of therapeutic relevance in SSc is evaluated.
1.Introduction
Systemic sclerosis (SSc)isa connectivetissue disease charac-
terised by ﬁbrosis,vasculopathy, and immunological abnor-
malities. Over recent years, it has become clear that inﬂam-
mation plays a crucial role in mediating the pathophysiolog-
ical process underlying SSc, especially early in the disease.
Endothelial cell activation and dysfunction are central to the
disease pathogenesis, may be driven by a proinﬂammatory
environment, and may result in the generation of a proﬁ-
brotic phenotype.
Interleukin-6 (IL-6) is a pleiotropic cytokine. In addition
to its role in the acute phase response, IL-6 has diverse roles
in driving chronic inﬂammation, autoimmunity, endothelial
cell dysfunction, and ﬁbrogenesis. Therefore, it is currently
attracting a great deal of interest in the rheumatology
community as a potential therapeutic agent in SSc, a disease
which at present lacks treatments directed at the underlying
pathogenesis.
Recent evidence has suggested that IL-6 may play impor-
tant roles in endothelial cell dysfunction and ﬁbrogenesis in
this disease, and clinical trials are currently being designed to
furtherexplorewhetherTocilizumab,amonoclonalantibody
directed against the IL-6 receptor, may be of therapeutic
beneﬁt to patients with SSc.
2.Interleukin-6Biology
Interleukin-6 biology is complex. Few cells express the inter-
leukin-6 receptor (IL-6R, gp80). This receptor is expressed
on hepatocytes, monocytes, B cells, and neutrophils in
humans. It is also found on a subset of T cells, but there is
evidence that T cells respond to IL-6 predominantly through
a process known as trans signalling [1].
Endothelial cells and ﬁbroblasts do not express the IL-
6R and are also thought to respond to IL-6 through trans
signalling [2]. sIL-6Rs exist in the serum and bind to IL-6
forming an IL-6/sIL-6R complex. Soluble IL-6R (sIL-6R) is
produced by two separate mechanisms, ﬁrstly by proteolytic
cleavage from the surface of neutrophils and secondly by
secretionfromneutrophilsandmonocytesofanalternatively
spliced version [3–6].
Although the regulation of the proteolytic cleavage of
sIL-6R has not been fully elucidated, it is known to be
stimulated by C-reactive protein (CRP). Cleavage from
the surface of neutrophils, but not monocytes, is also
stimulated by chemoattractants (interleukin-8 (IL8), C5a,
leukotriene B4 (LTB4), and platelet activating factor (PAF))
[7]. Proteolytic cleavage can occur via a TNFα, converting
enzyme-like enzyme although this does not account for all of
the proteolytic cleavage [7].2 International Journal of Rheumatology
We and others have shown that there is an increased
concentration of the neutrophil chemoattractant IL-8 in SSc
serum [8, 9], which may stimulate the release of sIL-6R from
neutrophils. In addition, there are reports in the literature
that LTB4 levels are elevated in the bronchoalveolar lavage
ﬂuid of patients with SSc lung disease [10], that may also
contribute to the generation of sIL-6R.
The IL6/sIL6R complex can bind to the gp130 receptor,
which is expressed ubiquitously on cells including endothe-
lialcellsandﬁbroblasts,toactivatethesignaltransducersand
activatorsoftranscriptionprotein3(STAT3)signallingpath-
way [1–11]. Endothelial cell activation via trans signalling
results in an increase in the expression of adhesion molecules
(intercellular adhesion molecule-1 (ICAM-1), vascular cell
adhesion molecule-1 (VCAM-1)), the release of chemokines
(IL-8 and monocyte chemotactic protein-1 (MCP-1)), and
the release of IL-6 [2–12]( Figure 1).
3. Interleukin-6 in Systemic Sclerosis
IL-6 is a cytokine with several potentially important roles
in the pathogenesis of SSc. It is elevated in the serum of
patients with systemic sclerosis, especially those with diﬀuse
skin involvement and early in the disease course [13, 14].
Immunocytochemistry studies have also demonstrated that
IL-6 may be elevated in lesional tissue later in the disease,
when other proinﬂammatory cytokines have dissipated.
Several other observations further support a role for
this interleukin in SSc. Fibroblasts isolated and cultured
from the lesional skin of patients with SSc constitutively
produce higher levels of IL-6 than nonlesional or healthy
donor ﬁbroblasts [15]. This demonstrates the importance
of considering local concentrations of cytokines in disease.
Serum concentrations may not necessarily reﬂect local levels
of a relevant cytokine at the lesional site. Hence, the use of in
vitromodelstoexplorelocalinteractionsbetweenﬁbroblasts,
endothelial cells, and immune cells, in the presence of locally
elevated levels of cytokines, is of particular importance.
Stimulated and unstimulated ﬁbroblasts from lesional skin
have also been shown to produce increased levels of IL-8
which may be implicated in local release of sIL-6R from
neutrophils [16].
Previous research has shown that peripheral blood
mononuclear cells from SSc patients, when cultured in vitro,
producehigherlevelsofIL-6andsIL-6Rintheculturesuper-
natants than control peripheral blood mononuclear cells,
though levels of sgp130 were equivalent [17]. Furthermore,
IL-6R levels were increased in the serum of patients with
limited cutaneous SSc (lcSSc) compared to controls [18].
IL-6 transcription is under the control of a hypoxic
response element via hypoxia-inducible factor-1-α (HIF-1-
α). Measurements taken from the lesional skin of patients
have demonstrated a persistent decrease in oxygen tension
[19],downtheequivalentof3%O2,suﬃcienttoinduceHIF-
1α signalling [19].
In addition, it is important to note that hemodynamic
ﬂow may suppress IL-6-induced signalling in endothelial
cells [20]. As such ﬂow is dysregulated in SSc, this may
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Figure 1: Interleukin-6 trans signalling. IL-6 receptors are
expressed on leukocytes including neutrophils, but they are not
expressed on tissue-resident cells, for example, endothelial cells.
Endothelial cells can respond to IL-6 through the gp130 receptor
only when the IL-6 is bound to a soluble IL-6 receptor (sIL-6R).
sIL-6Rsareformedbysecretionofanalternativelysplicedversionof
the receptor or proteolytic cleavage from the surface of neutrophils.
There is also a pool of soluble gp130 (sgp130) which can bind IL-
6/sIL6R complexes and prevent them binding to cellular gp130.
Therefore, the local concentrations of IL-6, sIL-6R, and sgp130
regulate IL-6 signalling.
play an important role in modulating the eﬀects of IL-6 on
endothelial cells in this disease.
4. Interleukin-6Effects on B Cells
IL-6 also has a profound eﬀect on B cells, promoting
plasma cell diﬀerentiation and antibody production. This
may explain the polyclonal B-cell expansion and hypergam-
maglobulinaemia which is frequently seen in SSc [11].
B-cell depletion using rituximab (monoclonal antibody
directedagainstCD20)in9patientswithprogressiveSScskin
disease, refractory to cyclophosphamide therapy, resulted in
a clinical improvement in skin score after 3 months, which
persisted up to 36 months. This was paralleled by a decrease
in serum IL-6 concentration [21].
5. Interleukin-6and Effects on Inﬂammation
IL-6 has been implicated in the generation and propagation
of chronic inﬂammation. Initially in acute inﬂammation,
proinﬂammatory cytokines promote neutrophil accumula-
tion and the release of IL-6. Neutrophils then shed their IL-
6Rs in response to chemokines such as IL-8. This promotes
diﬀerential regulation of chemokine production by endothe-
lial cells, promoting MCP-1 production and decreasing IL-8International Journal of Rheumatology 3
production,thereforefavouringmonocyteaccumulation.IL-
6 trans signalling also increases the expression of endothelial
leukocyte adhesion molecules (VCAM-1, ICAM-1), further
promoting leukocyte accumulation [12–22]. In addition, IL-
6 may have a role in promoting neutrophil apoptosis and
therefore the resolution of acute (nonspeciﬁc) inﬂammation
[23, 24]. Others however have reported an antiapoptotic
eﬀect of IL-6 on neutrophils [25], while Biﬄ et al. have
shown that the eﬀect depends on the neutrophil concen-
tration [26]. We have been unable to reproduce any IL-
6-speciﬁc eﬀect on neutrophil apoptosis in our laboratory
at concentrations of IL-6 ranging from 0.1 to 100ng/mL
(personal communication Helen Wright).
Conversely, IL-6 reportedly rescues T cells from apop-
tosis, which promotes a chronic inﬂammatory cell inﬁltrate
[27–30]. IL-6 trans signalling also promotes the release of IL-
6fromﬁbroblastsandendothelialcellsinapositiveautocrine
feedbacksystem.Therefore,itcanbeenvisagedthatIL-6may
havearoleinpropagatingchronicinﬂammation,suchasthat
seen in SSc. This is in keeping with immunocytochemical
experiments which demonstrate that IL-8 and IL-6 are over-
expressed in the lesional skin of patients with SSc, though
in diﬀerent patterns: the overexpression of IL-8 is associated
with early disease (<1yr), whereas IL-6 overexpression is
associated with later disease [31].
IL-6 has also been implicated in autoimmunity. Evidence
frompatientswithCrohn’sdiseaseindicatesthatautoreactive
T cells are resistant to apoptosis due to protection by IL-
6 trans signalling via the STAT3 signalling pathway [32].
IL-6 inhibits a Na2+/K+ ATPase which regulates antigen
internalisation and antigen presentation by dendritic cells
to T cells, which may promote presentation of autoanti-
gens [33, 34]. Finally, according to Matzinger’s “danger
theory,” na¨ ıve T cells die if they receive a signal from
proper antigen presentation that is not followed up by
ligation of CD40 [35]. There is evidence that IL-6/sIL-
6R complex can inappropriately substitute for this second
signal and therefore lead to the persistence of autoreactive
T cells [36]. Furthermore, autoimmune phenomena increase
with age, in concert with an age-related increase in sIL-
6R shedding [37]. Lissilaa et al. explored the role of IL-
6 in the collagen-induced arthritis (CIA) and antigen-
induced arthritis (AIA) models of autoimmune inﬂamma-
tory arthritis. Using antibodies which speciﬁcally blocked
classical IL-6 signalling and trans signalling pathways, they
discovered that the classical IL-6 pathway was both necessary
and suﬃcient for the development of pathogenic Th17 T
cells which are implicated in autoimmunity and for the
generation of antitype II collagen IgG responses which are
associated with disease manifestations in the CIA model.
They also demonstrated in the AIA model that IL-6 trans
signalling was responsible for driving local inﬂammatory
responses [38]. SSc is a disease associated with autoimmune
phenomena. Many diﬀerent autoantibodies are found in SSc
(see Table 1), and the autoantibody proﬁle in many cases
correlates with clinical manifestations. There is, however,
no convincing evidence for a direct role for autoantibodies
in pathogenesis though some investigators have reported
that antiendothelial cell antibodies, found in a proportion
Table 1: Systemic sclerosis-associated autoantibodies, potentially
pathogenic antibodies which have been described in a proportion
of patients with systemic sclerosis. Reviewed in [41]. ECM:
extracellular matrix.
Autoantibody In vitro activity
Antiendothelial cell Endothelial cell apoptosis
Antiﬁbrillin 1 Fibroblast activation, increased
ECM production
Antimatrix
metalloproteinase Prevent degradation of the ECM
Anti-PDGFR
Induce collagen 1 production
Convert ﬁbroblasts to
myoﬁbroblasts
Antiﬁbroblast Increased expression of ICAM
and IL-6
Anti-HSP47 Not known
of patients, are associated with endothelial cell activation
[39, 40].
6. Interleukin-6and Effects on Fibrogenesis
Fibroblasts from patients with SSc are phenotypically
unique. When isolated and cultured in vitro they continue to
p r o d u c ea ne x c e s so fc o ll a g e n[ 42, 43]. IL-6 is a proﬁbrogenic
cytokine. It has been shown to either increase or decrease
ﬁbroblast proliferation, increase ﬁbroblast collagen, gly-
cosaminoglycan, and tissue inhibitor of metalloproteinases-
1 (TIMP-1) synthesis, and increase MCP-1 and IL-6 pro-
duction [43–48]. IL-6 regulates the expression of vascular
endothelial growth factor (VEGF), an important mediator of
angiogenesis and ﬁbrosis which is elevated in patients with
SSc [49].
One case series has indicated that the use of tocilizumab,
which blocks IL-6 trans signalling, in 2 patients with diﬀuse
cutaneous SSc (dcSSc), one with renal involvement and
the other with lung ﬁbrosis, resulted in a decrease in skin
thickening as measured by Rodnan skin score and Vesmeter
(which measures viscoelasticity or hardness of the skin). In
addition, skin biopsies taken before and after tocilizumab
treatment indicated a reduction in collagen [50].
7.Interleukin-6andEffects onEndothelial
CellActivation
Endothelial activation is thought to be central to the
pathogenesis of SSc. There is also evidence for increased
endothelial cell apoptosis though corroborative in vivo
evidence for this is lacking [51]. The University of California
at Davis line 200 chicken, an animal model for SSc, shows
evidence of early endothelial cell apoptosis, preceding the
inﬂammatory cell inﬁltrate and the development of ﬁbrosis
[39–52].
Serum markers of endothelial cell activation, for exam-
ple, von Willebrand factor (vWF), sICAM-1, and sE-selectin
are elevated in the serum of patients with SSc and appear to
correlate with disease activity [53–55].4 International Journal of Rheumatology
PreviousstudieshaveshownaroleforIL-6inendothelial
cell activation. Endothelial cell activation via trans signalling
results in an increase in the expression of adhesion molecules
(ICAM-1, VCAM-1), the release of chemokines (IL-8 and
MCP), and the release of IL-6 [2–12].
We have recently shown that SSc serum, in the presence
of neutrophils, is capable of increasing endothelial cell
activation and apoptosis in an IL-6-dependent manner [56].
It is postulated that in this circumstance the neutrophils are
acting as donors of IL-6R. In our studies, spiking pooled
control serum with IL-6 resulted in increased endothelial
cell apoptosis and E-selectin expression in the presence of
neutrophils, mimicking the eﬀects of SSc serum. Comple-
ment inactivation did not abrogate the eﬀects of SSc serum,
neither did the addition of catalase to mop up reactive
oxygenspecies.TheserineproteaseinhibitorAEBSFpartially
blocked the eﬀects of SSc serum on endothelial cell apoptosis
but did not signiﬁcantly aﬀect the activation of endothelial
cells by SSc serum [56]. Strategies to remove or block the
eﬀects of IL6 in SSc serum including immunodepletion
of IL6 and the addition of an anti-IL6 blocking antibody
reversed the eﬀects of SSc serum on endothelial cell activa-
tion and apoptosis [56]. Most signiﬁcantly, however, sgp130
which speciﬁcally blocks IL6 trans signalling abrogated the
eﬀects of SSc serum [56].
8. Conclusion
IL-6 blockade and speciﬁcally the blockade of IL-6 trans-
signalling may have merit in the treatment of SSc, a disease
that so far lacks treatment options directly targeting the
pathogenic mechanism. IL-6 trans signalling is speciﬁcally
implicated in driving local inﬂammation and inducing
endothelial and ﬁbroblast responses, and therefore targeting
this IL-6 signalling pathway may be most proﬁtable in SSc.
However, SSc also has important and possibly pathogenic
autoimmune phenomena, and targeting the classical IL-6
signalling pathway may be necessary in order to inﬂuence
this important aspect of the disease. The currently available
drug Tocilizumab targets both the classical and the trans
signalling pathways. Other agents are in development which
speciﬁcally block trans signalling, and they may be useful in
mouse models of SSc to delineate which signalling pathway
is most important for this disease.
IL-6 is increased in the serum of patients with SSc,
especially in early dcSSc. In addition, it is also found in
immunohistochemistry samples in both early and late dis-
ease and in both dcSSc and lcSSc. Fibroblasts and monocytes
isolated from SSc patients autonomously produce IL-6 in
vitro.
Early, small-scale nonrandomised controlled trials point
to an important role for IL6 in SSc. B-cell depletion results in
a decrease in serum IL-6 levels, reﬂected in a simultaneous
reduction in skin score. More importantly, blocking IL-
6 trans signalling with Tocilizumab has resulted in an
improvement in skin score in 2 patients with diﬀuse disease.
These data ﬁrmly establish IL-6 as an attractive candidate
therapeutic target, especially in terms of preventing ﬁbrosis.
However, in addition, new and exciting data imply that
IL-6 has a role in the endothelial and inﬂammatory manifes-
tations of this disease, which may make it a potential
target in a much broader range of SSc patients with active
vascular or inﬂammatory (e.g., joint) disease but relatively
little ﬁbrosis. Studies are being designed to address these
important questions; the results are eagerly awaited.
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